Global Companion Diagnostics Market By Product and Services (Assay Kits and Reagents, Software & Services), Technology (Polymerase Chain Reaction, Immunohistochemistry, Next-Generation Sequencing, In Situ Hybridization), Indication (Oncology {Breast Cancer, Lung Cancer, Colorectal Cancer, Gastric Cancer, Melanoma} Neurology, Infectious Diseases), End Users (Pharmaceutical and Biopharmaceutical Companies, Reference Laboratories), Geography (North America, Europe, Asia-Pacific, Europe, South America, Middle East and Africa) – Industry Trends and Forecast to 2024

Pune, India -- (SBWire) -- 02/07/2018 --The Global Companion Diagnostics Market accounted to USD 9.40 billion in 2024, growing at a CAGR of 19.8% during the forecast period of 2017 to 2024. The upcoming market report contains data for historic year 2015, the base year of calculation is 2016 and the forecast period is 2017 to 2024.

Companion Diagnostics Market Definition:

Companion diagnostics are in-vitro diagnostics that provide information about therapeutic treatment of patients through which they can be benefitted from certain drug dosage according to their diagnosis, allergies and necessity. Here much technological advancement has been made in order to improve this along with the growing requirements for enhanced personalized patient treatment so that complete assurance must be given by the doctors.

Get PDF Brochure @ http://databridgemarketresearch.com/request-a-sample/?dbmr=global-companion-diagnostics-market            

Major Market Drivers and Restraints:



- Increasing number of genetic testing

- Growing technological development

- Increase in cost related to technological advancement


Companion Diagnostics Market Segmentation:

On the basis of product and services, global companion diagnostics market is segmented into assay kits and reagents and software & services.

On the basis of technology, global companion diagnostics market is segmented into polymerase chain reaction, immunohistochemistry, next-generation sequencing and in situ hybridization.

On the basis of indication, global companion diagnostics market is segmented into oncology, neurology and infectious diseases whereas; oncology is sub segmented into breast cancer, lung cancer, colorectal cancer, gastric cancer and melanoma.

On the basis of end users global companion diagnostics market is segmented into pharmaceutical and biopharmaceutical companies and reference laboratories.

On the basis of geography, global companion diagnostics market report covers data points for 28 countries across multiple geographies namely North America & South America, Europe, Asia-Pacific, and Middle East & Africa. Some of the major countries covered in this report are U.S., Canada, Germany, France, U.K., Netherlands, Switzerland, Turkey, Russia, China, India, South Korea, Japan, Australia, Singapore, Saudi Arabia, South Africa, and Brazil among others. In 2017, North America is expected to dominate the market.

Have Any Query? Ask Ours Expert @ http://databridgemarketresearch.com/speak-to-analyst/?dbmr=global-companion-diagnostics-market            

Companion Diagnostics Market Competitive Analysis:

The global companion diagnostics market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes companion diagnostics shares for global, Europe, North America, Asia Pacific, and South America.

Major Market Competitors:

Some of the major players operating in companion diagnostics market are F. Hoffmann La Roche Diagnostics, QIAGEN , Abbott, Agilent Technologies,  Ventana Medical Systems Inc., Myriad Genetics, Leica Biosystems Nussloch GmbH, RESONANCE HEALTH, ARUP Laboratories, Life Technologies, Thermo Fisher Scientific Inc., and bioMerieux SA among others.

Know More About our Knowledge Store @ http://databridgemarketresearch.com/reports/global-companion-diagnostics-market/